anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Ketamine
Trial phase: Phase 2
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.

ketamine: sedative
Eligibility criteria:
Inclusion Criteria:

Male or female Veterans aged 18 to 75 years.
Have a telephone in their home and able to hear telephone conversations.
Must meet current DSM-IV criteria for major depressive disorder (MDD), single or recurrent, without psychotic features confirmed by depression subset of the Structured Clinical Interview-Clinical Trial for DSM-IV (SCID).
Have score 32 on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30)for severity of major depressive episode (MDE) at screening.
Current major depressive episode resistant to treatment defined as failure to achieve improvement from at least 2 antidepressant trials of different pharmacological classes. Systematic evaluation of previous antidepressant trials will be assessed by the Antidepressant Treatment History Form (ATHF) .
If applicable, current antidepressant dosages including augmenting agents and/or frequency and duration of psychotherapy sessions must remain stable for at least 6 weeks prior to beginning of the study.

Exclusion Criteria:

Inability to speak English.
Inability or unwillingness to provide written informed consent.
Moderate/severe cognitive impairment by Mini Mental State Examination (MMSE) scores 27.
Current or lifetime DSM-V criteria for post-traumatic stress disorder (PTSD), acute stress disorder, psychosis-related disorder, bipolar disorder I or II disorder, substance-induced mood disorder, any mood disorder due to a general medical condition or any Axis I disorder other than MDD as the primary presenting problem.
History of moderate or severe traumatic brain injury, Parkinson's disease, dementia of any type, multiple sclerosis, seizures or other central nervous system (CNS) related disorders.
History of comorbid substance disorder within 6 months of assessment plus positive urine toxicology screen test during baseline assessments.
Clinically unstable medical illness that could compromise the patient's ability to tolerate or likely interfere with the study procedures (e.g., history of or current myocardial ischemia or arrhythmias, congestive heart failure, severe pulmonary, renal, or hepatic disease, uncontrolled hypertension).
Current or within less than 14 days use of barbiturates or monoamine oxidase inhibitors (MAOi).
For women: pregnancy (confirmed by lab test), initiation of female hormonal treatments within 3 months of screening, or inability/ unwillingness to use a medically accepted contraceptive method during the study.
Imminent risk of suicidal/homicidal ideation and/or behavior with intent and/or plan.
Intervention: Clonidine
Trial phase: Phase 4
ATC code: C02AC01 | C02LC01 | C02LC51 | N02CX02 | S01EA04
SMILES: Clc1cccc(Cl)c1NC1=NCCN1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 191
Group description: Clonidine : injection og 3 micg/kg IV during the operation.

Clonidine: Injection - during surgery
Eligibility criteria:
Inclusion Criteria:

scheduled for surgery with Sevoflurane as the choice of anesthesia.

Exclusion Criteria:

ASA classification >2
Premedication with Clonidine
Ex-premature (born before week 37+0 AND <60 weeks old)
Intubated before anaesthesia and/or no plans for extubation after anaesthesia.
Critical illness with haemodynamic instability.
Active bleeding.
Cancer.
Cardiac diseases including arrhythmias.
Malignant hyperthermia.
Mental retardation.
Neurological illness with agitation-like symptoms.
Weight >50 kg.
Allergy to Clonidine.
Patients treated with methylphenidate / Concerta.
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 120
Group description: Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery

Lactate Ringers: Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
Eligibility criteria:
Inclusion Criteria:

Old patients scheduled to undergo orthopaedic surgery under a intravertebral anesthesia. (American Society of Anesthesiologists physical status I-Ⅲ)

Exclusion Criteria:

Allergy and contraindication to HES
Infections and malignancies
Sepsis
History of heart failure or New York Heart Association(NYHA)>Ⅲ
Renal failure or Cr>108μmol/L，BUN>8.3mmol/L
Undergoing dialytic treatments
Intracranial hemorrhages
Taking non-steroidal antiinflammatory agent for a long time
Inability to understand the Study Information Sheet and provide a written consent to take part in the study
Intervention: Tyrosine
Trial phase: Not Applicable
SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 120
Group description: 6% Hydroxyethyl Starch (HES) is intravenously administrated at a dose of 7.5ml/ kg in the first hour of surgery, and then, Lactate Ringers' is administrated to the patient until the end of the surgery

Hydroxyethyl Starch: 6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
Eligibility criteria:
Inclusion Criteria:

Old patients scheduled to undergo orthopaedic surgery under a intravertebral anesthesia. (American Society of Anesthesiologists physical status I-Ⅲ)

Exclusion Criteria:

Allergy and contraindication to HES
Infections and malignancies
Sepsis
History of heart failure or New York Heart Association(NYHA)>Ⅲ
Renal failure or Cr>108μmol/L，BUN>8.3mmol/L
Undergoing dialytic treatments
Intracranial hemorrhages
Taking non-steroidal antiinflammatory agent for a long time
Inability to understand the Study Information Sheet and provide a written consent to take part in the study
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).

Dexamethasone: Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
Eligibility criteria:
Inclusion Criteria:

18 years and older
evidence of subacute or chronic supratentorial subdural hematoma by CT (computerized tomography) scan or MRI (magnetic resonance imaging)
classified between 0 and 2 using the Markwalder grading scale

Exclusion Criteria:

contraindications or intolerance to corticosteroid therapy
patients already undergoing steroid treatment for any other indication
previous neurological surgery up to one year prior to being considered for the study
concomitant cerebral pathology of neoplastic or presumed infectious origin
anticoagulant therapy that could not be stopped for 6 months
refusal to participate in the study
Intervention: Buspirone
Trial phase: Early Phase 1
ATC code: N05BE01
SMILES: O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Participants received bouspirone 20 mg/day for 4 weeks
Eligibility criteria:
Inclusion Criteria:

SSc patients with esophageal symptoms

Exclusion Criteria:

none
Intervention: Lidocaine
Trial phase: Not Applicable
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.

lidocaine: lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
Eligibility criteria:
Inclusion Criteria:

Age ≥18;
Diagnosis of Diabetes Mellitus (Fasting Plasma Glucose > 126 mg/dL and/or HbA1C >6.5%);
Distal symmetric pain in lower extremities with duration of more than 3 months;
Presence of either numbness or at least 1 sensory disturbance (increased or decreased sensitivity) in the feet.
Spontaneous pain with intensity of ≥ 4 on 0-10 Numerical Rating Scale (NRS).

Exclusion Criteria:

Not giving consent to participate in the study;
Unable to complete self-report pain questionnaire;
History of moderate to severe renal or liver failure;
History of other central or peripheral neurologic disorders;
History of cardiac arrhythmias;
Contraindication to intravenous lidocaine;
Pregnancy or lactation.
Intervention: Nalmefene Hydrochloride
Trial phase: Phase 3
SMILES: C=C1CCC2(O)C3Cc4ccc(O)c5c4C2(CCN3CC2CC2)C1O5.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 248
Group description: Nalmefene hydrochloride: As-needed; tablets, orally
Eligibility criteria:
Inclusion Criteria:

Japanese males and females aged 20 or above who have signed the informed consent form
The patient has alcohol dependence, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) and confirmed by Mini-international Neuropsychiatric Interview (M. I. N. I.)
The patient has a drinking risk level of High or above (> 60 g for men and > 40 g for women) both at the Screening Visit and at the Randomization Visit .

Exclusion Criteria:

The patient with a current diagnosis or history of substance use disorders (except for alcohol, nicotine, and caffeine), according to DSM-IV-TR and confirmed by M. I. N. I.
The patient has reported current use of, or has tested positive for, drugs of abuse (opiates, methadone, cocaine, amphetamines, barbiturates) at the screening test
Intervention: Nalmefene Hydrochloride
Trial phase: Phase 3
SMILES: C=C1CCC2(O)C3Cc4ccc(O)c5c4C2(CCN3CC2CC2)C1O5.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 184
Group description: Nalmefene hydrochloride: As-needed; tablets, orally
Eligibility criteria:
Inclusion Criteria:

Japanese males and females aged 20 or above who have signed the informed consent form
The patient has alcohol dependence, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) and confirmed by Mini-international Neuropsychiatric Interview (M. I. N. I.)
The patient has a drinking risk level of High or above (> 60 g for men and > 40 g for women) both at the Screening Visit and at the Randomization Visit .

Exclusion Criteria:

The patient with a current diagnosis or history of substance use disorders (except for alcohol, nicotine, and caffeine), according to DSM-IV-TR and confirmed by M. I. N. I.
The patient has reported current use of, or has tested positive for, drugs of abuse (opiates, methadone, cocaine, amphetamines, barbiturates) at the screening test
Intervention: Pioglitazone
Trial phase: Phase 4
ATC code: A10BD05 | A10BD06 | A10BD09 | A10BD12 | A10BG03
SMILES: CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: (Pioglitazone, 15 mg/day)

Pioglitazone: Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Eligibility criteria:
Inclusion Criteria:

Subject has provided informed consent in a manner approved by the Institutional Review Board (IRB) and is willing and able to comply with the trial procedures.
Adults at least 18 years of age at the time of consent.
Have type 2 diabetes mellitus.
Be on a stable medication with metformin (2000 mg/day) for at least 3 months prior to study enrollment.
Have blood A1c >7.6% and < 8.5% within 3 months prior to study enrollment.
Have fatty liver, which is diagnosed by ultrasonographic findings of "bright liver" within 1 year of study enrollment.
Stable medication for lipid lowering, blood pressure control, dietary supplements, including vitamins, for at least 3 months.
Women of Childbearing Potential must be willing and able to use acceptable forms of birth control while on the study.

Exclusion Criteria:

Currently taking medication that can affect glucose metabolism other than Metformin.
History of Kidney diseases that, in the opinion of the investigator , would place the subject at increased risk of participation or plasma levels of creatinine > 1.4 for women and > 1.5 for men.
History of Cirrhosis of liver, hepatitis, or other liver diseases that, in the opinion of the investigator, would place the subject at increased risk of participation.
Current alcohol consumption more than12 to 15 g of alcohol a day, or >12 oz of beer, 5 oz of wine, or 1.5 oz of distilled spirits.
History of heart failure.
Concurrent participation on another research study
Use of an investigational agent in the 30 days prior to signing informed consent.
History of prior non-compliance or the presence or history of psychiatric conditions (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the subject to comply with the study procedures or follow the investigators instructions.
Females who are pregnant or lactating
Current Diagnosis or History of Bladder Cancer
Intervention: Rotigotine
Trial phase: Phase 4
ATC code: N04BC09
SMILES: CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: rotigotine transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks

rotigotine transdermal patch: Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
Eligibility criteria:
Inclusion Criteria:

Diagnosis of Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 Anxiety Disorder
Stable medical history and general health
On stable anti-parkinsonian therapy for 2 weeks before enrollment

Exclusion Criteria:

Unstable medical disease of comorbid psychiatric disease
Dementia
Subjects with less than one year duration of Parkinson's
Current treatment with a dopamine agonist
Intervention: Ropivacaine
Trial phase: Phase 4
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 43
Group description: Local anesthetic in the hip joint consisting of 30cc of 0.5% Noropin

Noropin
Eligibility criteria:
Inclusion Criteria:

Scheduled for outpatient hip arthroscopy
American Society of Anesthesiologists (ASA) 1-3

Exclusion Criteria:

Prior surgery on ipsilateral hip
ASA 4-6
Chronic narcotic usage over 6 months or more than the equivalent of 20mg of morphine per day
Current or prior placement of a spinal cord stimulator or intrathecal pump for pain control purposes
Allergy to amide local anesthetics
Contraindication to regional anesthesia
BMI > 40
Females who are pregnant or plan to get pregnant during the course of the study
Intervention: PF-03715455
Trial phase: Phase 2
SMILES: CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: PF-03715455 680 mcg dry powder capsule was administered by oral inhalation twice daily via a Miat mondose inhaler device for 4 weeks in each treatment period. Dosing in each treatment period was separated by a washout period of 28 to 49 days.
Eligibility criteria:
Inclusion Criteria:

Female subjects of non-childbearing potential and male subjects between the ages of 40 and 80 years, inclusive
Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD and who meet the criteria for Stage II-III disease
Subjects must have a smoking history of at least 10 pack-years

Exclusion Criteria:

Current evidence or history within the previous 6 months of any clinically significant disease (other than COPD) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data
A COPD exacerbation requiring treatment with oral steroids or hospitalization for the treatment of COPD within 3 months of Screening
Intervention: Elamipretide
Trial phase: Phase 1 | Phase 2
SMILES: Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days
Eligibility criteria:
Inclusion Criteria:

Diagnosis of mitochondrial disease believed to impair the mitochondrial respiratory chain.
Eligibility requires prior genetic confirmation of mitochondrial disease.
Diagnosis of mitochondrial myopathy judged by the Investigators to be due to existing mitochondrial disease.
Must be able to complete a Screening Visit 6MWT.
Body mass index (BMI) score >15.0 and <35.0 kg/m2 at Screening Visit.
Women of childbearing potential must agree to use birth control as specified in the protocol from the date they sign the ICF until two months after the last dose of study drug.

Exclusion Criteria:

Any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all study requirements.
Had any exclusionary Newcastle Mitochondrial Disease Adult Scale (NMDAS) scores at Screening Visit.
Hospitalized (admitted as in-patient) within 1 month prior to the Baseline Visit.
A history of type 1 diabetes mellitus (T1DM).
Uncontrolled Type 1 (T1DM) or Type 2 diabetes mellitus (T2DM), in the opinion of the investigator.
A creatinine clearance <45 mL/min as calculated by the Cockcroft Gault equation.
Requires pacemaker, defibrillator, or has undergone cardiac surgery within 2 years of Screening Visit.
QTc elongation defined as a QTc >450 msec in male subjects and >480 msec in female subjects.
Uncontrolled hypertension (>160 mmHg systolic or >100 mmHg diastolic) at Screening Visit.
History of rhabdomyolysis defined as an acute rise in the serum creatine phosphokinase (CPK) value that, in the opinion of the investigator, caused clinically significant symptoms.
Serum sodium more than 5 meq/L below the reference lower limit of normal at Screening Visit.

Participated in another interventional clinical trial within 3 months of the screening visit or is currently enrolled in a non-interventional clinical trial judged by the Investigator to be incompatible with the current trial.

Other protocol-defined inclusion/exclusion criteria may apply.
Intervention: Testosterone
Trial phase: Phase 3
ATC code: G03BA03 | G03EA02
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H]
Sex: Male
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 42
Group description: Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training

Testosterone: Daily testosterone gel applied once daily in the morning to intact skin

Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week
Eligibility criteria:
Inclusion Criteria:

Subjects will be

older (65-85 yr)
obese (BMI 30 kg/m2 or greater) Veteran men with low testosterone (less than 300 mg/dL) as defined by the Endocrine Society
mild to moderately frail
must have stable weight (~not less than or more than 2 kg) during the last 6 months
sedentary (regular exercise less than 1 h/week or less than 2x/week for the last 6 months)

Exclusion Criteria:

Any major chronic diseases, or any condition that would interfere with exercise or dietary restriction, in which exercise or dietary restriction are contraindicated, or that would interfere with interpretation of results.

Examples include, but are not limited to:

cardiopulmonary disease (e.g. recent myocardial infarction (MI), unstable angina, stroke etc) or unstable disease (e.g. CHF)
severe orthopedic/musculoskeletal or neuromuscular impairments
visual or hearing impairments
cognitive impairment (Mini Mental State Exam Score less than 24)
current use of bone active drugs
uncontrolled diabetes (i.e. fasting blood glucose more than 140 mg/dl and/or HbA1c greater than 9.5%).

Any contraindications to testosterone supplementation

history of prostate or breast cancer
history of testicular disease
untreated sleep apnea
hematocrit more than 50%
prostate-related findings of palpable nodule on exam, a serum PSA of 4.0 ng/ml or greater
International Prostate Symptom Sore more than 19
history of venous thromboembolism
Osteoporosis or a BMD T-score of -2.5 in the lumbar spine or total hip as well as those patients with a history of osteoporosis-related fracture (spine, hip, or wrist)
Intervention: Biotin
Trial phase: Phase 4
ATC code: A11HA05
SMILES: [H][C@]12CS[C@@H](CCCCC(=O)O)[C@@]1([H])NC(=O)N2
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 48
Group description: Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.
Eligibility criteria:
Inclusion Criteria:

All subjects must meet CCTG 595 inclusion criteria.

Exclusion Criteria:

All subjects must meet CCTG 595 exclusion criteria.
Current or prior use of bisphosphonate therapy.
Current use of Vitamin D supplements greater than 400 IU/day.
Current use of androgenic hormones or growth hormones.
History of nephrolithiasis (kidney stones).
History of fragility fracture.
No use of tenofovir prior to entry into CCTG 595